Panelists discuss how the evolution of anal cancer treatment began with the 1974 Nigro regimen combining 5-fluorouracil and ...

A panelist discusses how the most effective therapy for squamous cell anal carcinoma is prevention through human ...

Panelists discuss how successful treatment of locally advanced anal cancer requires a multidisciplinary approach involving colorectal surgeons, radiation oncologists, pathologists, medical oncologists ...

Bangalore: AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organisation ...

A phase 3 trial of Johnson & Johnson's TAR-200 therapy in bladder cancer has failed to show efficacy, although the company is still confident in the potential of the programme. The SunRISe-2 study ...

SANO suggests chemoradiation carries a 91·4% rate of failure, depends on 60% false-negative surveillance, and, compared with surgery, has a 16-month shorter survival, 9% higher rate of metastases, and ...

The SANO study by Berend J van der Wilk and colleagues showed non-inferiority of the non-surgical approach if complete clinical response was reached with chemoradiation in patients with resectable ...

Patients with the rare blood cancer, Waldenstrom macroglobulinemia (WM), who are living in rural or socioeconomically deprived areas may experience worse outcomes, according to Alisha Kimble, senior ...

At the 2025 ASCO Annual Meeting, Dr. Emre Yekedüz, a medical oncologist and research fellow at Dana-Farber Cancer Institute, emphasized that the future of kidney cancer care is increasingly centered ...

Harnessing the greater lethality of alpha-emitting radioisotope payloads represents a significant advancement in radiopharmaceuticals. Alpha emitters deliver high-energy decay with limited tissue ...

Find the latest Rafael Holdings, Inc. (RFL) stock quote, history, news and other vital information to help you with your stock trading and investing.